The combination of YKL-5-124 and an immune-checkpoint blockade can effectively inhibit the proliferation of SCLC; this provides a theoretical basis for a promising combination therapy consisting of CDK7 inhibition and anti-PD-1 antibody application in SCLC treatment (84). This evidence concerns the gene CDK7 and small cell lung carcinoma.